Vijayakrishna Gadi, MD, PhD, sets the stage for a discussion around HER2-directed ADCs in the solid tumor space.
EP. 1: Assessing HER2 Status Across Tumor Types
Dr Gadi leads a discussion surrounding HER2 mutation and overexpression across various cancer types.
EP. 2: ADCs Targeting HER2+ Breast Cancer
Dr Gadi introduces treatment and trial data targeting care for patients diagnosed with HER2+ breast cancer.
Dostarlimab/Chemo Shows OS Benefit Regardless of MMR Status in Endometrial Cancer
Perioperative Pembrolizumab/Chemo Regimen Yields Superior OS in Resectable Gastric Cancer
First-Line Tislelizumab Plus Chemotherapy Shows OS Benefit in PD-L1+ ESCC Subgroups
IBI343 Is Safe, Generates Preliminary Efficacy in CLDN18.2+ Advanced Gastric/GEJ Adenocarcinoma